Search Results

Nexalin Technology, Inc. announced the pricing of a public offering of 3,000,000 shares of common stock at public offering price of $1.75.

Nexalin Technology, Inc. announced that its second generation, 15 milliamp neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency, a regulatory body of the Brazilian government responsible for approving new drugs and medical devices.

Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced today that it will be participating in the Spring MicroCap Rodeo Conference, that will be held on Thursday, June 6, 2024 in New York City.

Nexalin Technology, Inc. is pleased to invite investors to a webinar on May 23, 2024, at 4:15 p.m. ET.

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced positive results of a clinical study designed to evaluate the feasibility, safety, and efficacy of transcranial alternating current dynamic frequency stimulation (tACS) as an add-on treatment for the symptoms of major depressive disorder (MDD), also known as clinical depression, a mental health condition that affects mood, behavior, appetite, and sleep.

Nexalin Technology, Inc. announced that the Company received notice from The Nasdaq Stock Market on April 23, 2024, notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Rule 5550.